FROM NATURAL HISTORY TO POST-APPROVAL EVIDENCE: AN INTEGRATED MULTI-SOURCE REAL-WORLD PROGRAM CHARACTERIZING IGA NEPHROPATHY IN THE ERA OF ORAL TARGETED-RELEASE FORMULATION OF BUDESONIDE

budesonide - Generic mfg.

Tarpeyo (budesonide) - Calliditas, Stada

https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2026/poster-session-2-4/from-natural-history-to-post-approval-evidence-an-integrated-multi-source-real-world-program-characterizing-iga-nephropathy-in-the-era-of-oral-targeted-release-formulation-of-budesonide

Giancarlo Pesce, PhD 1; Lobat Hashemi, PhD 2; Ramin Tolouian, MD 3; Margaret Helmuth, PhD 4; Artak Khachatryan, MPH, PhD, MD 5; Ananth Kadambi, MS, PhD 6; Terri Madison, PhD 7

Mar 6, 2026